RBBP4 and RBBP7 (RBBP4/7) are highly homologous nuclear WD40 motif containing proteins widely implicated in various cancers and are valuable drug targets. They interact with multiple proteins within diverse complexes such as NuRD and PRC2, as well as histone H3 and H4 through two distinct binding sites. FOG-1, PHF6 and histone H3 bind to the top of the donut shape seven-bladed β-propeller fold, while SUZ12, MTA1 and histone H4 bind to a pocket on the side of the WD40 repeats. Here, we briefly review these six interactions and present binding assays optimized for medium to high throughput screening. These assays enable screening of RBBP4/7 toward the discovery of novel cancer therapeutics.
Introduction
Retinoblastoma binding protein 4 (RBBP4) and 7 (RBBP7) also known as Retinoblastoma Associated protein 48 (RbAp48) and 46 (RbAp46), respectively, are highly homologous nuclear WD40 motif containing proteins 1, 2 . RBBP4 and 7 (RBBP4/7) have been widely implicated in various cancers and are valuable drug targets. Elevated levels of RBBP7 in nonsmall cell lung cancer, and inhibition of migration ability of lung cancer cells upon RBBP7 knockdown have been reported 3 . RBBP7 is also overexpressed in other cancers such as renal cell carcinoma, medulloblastoma and breast cancer [4] [5] [6] . Upregulation of RBBP7 in bladder cancer results in a cell invasion phenotype, and a decrease in its expression inhibited cell invasion 7 . RBBP4 is also overexpressed in several cancers including hepatocellular carcinoma 8 , and acute myeloid leukemia 9, 10 . Reduction of RBBP4 expression using siRNA resulted in the suppression of tumorigenicity. In human thyroid carcinoma, RBBP4 expression is upregulated and its downregulation suppressed tumorigenicity 11 . RBBP4 suppression in glioblastoma cells also enhanced sensitivity towards temozolomide chemotherapy 12 .
RBBP4 and RBBP7 are highly homologous proteins with similar structures (89% sequence identity). They are donut shaped proteins with a seven-bladed β-propeller fold typical for WD40-repeat proteins. Distinct features include a prominent N-terminal α-helix, a negatively charged PP-loop and a short C-terminal α-helix. Two binding sites have been identified on these two proteins, a c-site on the top of the WD40 repeats ( Fig.1A ) [13] [14] [15] and another located on the side of the WD40 domain between the N-terminal α-helix and PP-loop (Ser-347 to Glu-364 in RBBP7)
( Fig. 1B ) [15] [16] [17] . RBBP4/7 are components of several multi-protein complexes involved in chromatin remodeling, histone post-translational modifications and regulation of gene expression suggesting diverse functions for RBBP4/7. Such complexes include nucleosome remodeling and deacetylase (NuRD) complex 18 , switch independent 3A (Sin3A) 19 , and polycomb repressive complex 2 (PRC2) 20, 21 . Some interaction partners of RBBP4/7 include Metastasis Associated Protein 1 (MTA1) 18, 22 , also a component of NuRD complex, and suppressor of zeste 12 (SUZ12) 15, 21 within the PRC2 complex. Structural studies have shown that these interactions along with binding to histone H4 17 are through the side pocket on the WD40 domain of RBBP4/7
and Nurf55 (Drosophila RBBP4/7) (Fig. 1B) . In addition, the C-terminal α-helix may be involved in binding of peptides to this site. This pocket is unique to RBBP4/7. It has both negatively charged and hydrophobic areas (Fig. 2) Furthermore, all peptides adopt the same binding pose (Fig.1A) . This observation suggests that PHF6, FOG-1 and H3 interactions with RBBP4/7 and Nurf55 are highly conserved.
Interacting proteins

MTA1
The NuRD complex represses the transcription of several genes. 16 . Values for MTA1 (656-686) are provided in Table 1 for comparison.
SUZ12
PRC2 (Polycomb Repressive Complex) catalyzes the trimethylation of histone H3 lysine 27 (H3K27), which results in transcriptional silencing 36, 37 . PRC2 consists of a core complex of three subunits, EZH1/2 (enhancer of zeste homologue 1/2, the catalytic histone methyltransferase subunit), EED (embryonic ectoderm development) and SUZ12 (suppressor of zeste 12).
Additional proteins interact with the core complex, including RBBP4/7 38 . EZH2 activity requires interaction with both EED and SUZ12 39 . Overexpression of EZH2 has been reported in prostate and breast cancer which is associated with advanced stage and poor prognosis. Similarly, EZH2
is upregulated in various solid malignancies including renal cell carcinoma 40 , lung 41 , hepatocellular 42 and pancreatic 43 cancers. Knock-out studies performed with respect to the components of the PRC2 complex in mice and flies show that PRC2 and all its components are essential for viability as the knockouts exhibit embryonic lethality [44] [45] [46] . Thus, PRC2 is essential during the early stages of embryogenesis and it regulates the expression of several developmental genes 47, 48 . A study from Suz12 conditional knockout mice shows that Suz12 is important for the maintenance of hematopoietic stem cells and required for the development of the lymphoid lineage but not myeloid cells 49 . AEBP2 which serves as an associating component of PRC2 complex also interacts with RBBP4 and SUZ12, stabilizing the core PRC2 complex and increasing the methyltransferase activity of PRC2. 39 It has been shown that the three zinc fingers and RRK rich motif of AEBP2 interact with RBBP4. 50 RBBP4 binds to AEBP2 (379-390)
peptide with a dissociation constant of 7.6 ± 0.6 μM through the c-site on the top of the WD40
repeats. 50 The crystal structures of heterotetrameric complex consisting of SUZ12, RBBP4, Jarid2, and AEBP2 fragments have recently been reported as well.
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BCL11A is another protein that interacts with PRC2 and NuRD and SIN3A complexes through binding to RBBP4. BCL11A competes with histone H3 for binding to the top binding site on RBBP4. However, unlike histone H3, the crystal structure of RBBP4 in complex with a BCL11A peptide (residues 2-16) shows additional novel interactions between BCL11A and the side of the propeller of RBBP4 through residues 14 to 16 of BCL11A.
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PHF6
PHF6 is an X-chromosome encoded protein with nuclear and nucleolar localization, which is highly conserved among vertebrates. It consists of two atypical zinc-finger domains, called extended PHD (ePHD) domains (zinc knuckle, C2HC-type coordinating one zinc ion and an atypical PHD or ZaP) [53] [54] [55] . ePHD1 and ePHD2 share a sequence identity of 49% 56 . Although the canonical PHD domain can bind to histones, studies with ePHD2 have shown that it does not bind to any histone, but can bind to dsDNA in a non-sequence-specific manner 54 . From murine studies, PHF6 has been shown to be highly expressed in the embryonic central nervous system including brain and anterior pituitary, and its localization shifting from nucleus and cytoplasm during development to exclusively nuclear in adult 57 . Knockdown studies indicate a role for PHF6 in cell proliferation and neuronal migration 58, 59 . Clinically, PHF6 mutations have been implicated in two intellectual disability disorders, namely, Börjeson-Forssman-Lehmann Syndrome (BFLS) and Coffin-Siris Syndrome, in addition to T-Cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hepatocellular carcinoma, B-cell acute lymphoblastic leukemia (B-ALL), myelodysplastic syndromes and myeloid neoplasmas. [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] PHF6 is a potential oncogene which is overexpressed in various cancers such as colon, breast, stomach and glioma 71 . Its suppression in B-cell malignancies has been reported to impair tumor progression 72 . Lower expression of PHF6 has also been reported in some other cancers such as esophagus cancer 71 .
PHF6 interaction partners (NuRD complex, PAF-1 and UBF) exist both in the nucleoplasm and the nucleolus. From the NuRD complex, PHF6 was shown to co-purify with CHD3, CHD4, RBBP4, RBBP7 and HDAC1, wherein, PHF6 interaction with RBBP4 and CHD4 was restricted to the nucleoplasm, despite its presence in the nucleolus as well 53 . Among the various co-purified components of the NuRD complex, a direct interaction has been reported between RBBP4 and PHF6 and the interaction has been characterized both structurally and biophysically 13, 54 . A structure of full-length RBBP4 in complex with a PHF6 peptide (157-171 amino acids) showed that a negatively charged surface at the top of the RBBP4 β-propeller is essential for binding to a PHF6 peptide (a dissociation constant of 7.1 ± 0.4 µM; Table 1 ) 13 . Functionally, it was shown that the PHF6 region spanning amino acids 145 to 207 was sufficient for repressing the genes to which it was targeted, and its interaction with RBBP4 was required for the process 13, 54 .
FOG-1
FOG-1 is a 1006 amino acid protein that consists of nine zinc fingers, which are involved in mediating interactions with other proteins [73] [74] [75] [76] . Within the NuRD complex, FOG-1 has been
shown to directly interact with RBBP4. This interaction has been characterized biophysically and structurally. The N-terminus residues of FOG-1 (1-12 amino acids) have been shown to bind to RBBP4 with a K D of 0.6 ± 0.13 µM 14 (Table 1) .
FOG-1 has been shown to be largely functional in the hematopoietic system, in addition to other tissues such as male gonads, heart, and intestine (reviewed in 77 ). Accordingly, it is important for erythropoiesis and megakaryopoiesis and repressing myelo-lymphoid differentiation 78 . FOG-1 knockout mice are embryonically lethal due to severe anemia 79 . FOG-1 interaction with GATA1
has been well studied and reports also suggest its co-expression with GATA2, 3 and 4 (reviewed in 77 ). Disruption in its interaction with GATA-1 results in familial dyserythropoietic anemia and thrombocytopenia 80 . FOG-1 has been shown to act both as a co-activator or a co-repressor for its target genes (summarized in 77 ). 81 FOG-1 is also capable of upregulating the expression of genes that are otherwise repressed by GATA3 82 . In addition to GATA factors, FOG-1 interacts with, and recruits co-repressor complexes, NuRD complex and C-terminal binding protein (CtBP) 83, 84 .
Binding to Histone H3 and H4
Structural data shows that the 'side' surface of RBBP7 (and Nurf55) β-propeller interacts with a H4 peptide and this interaction requires unfolding of helix 1 of histone H4. It has been suggested that this unfolding would be required when H3 is present alone or in a complex (for example, in the nucleosome, or with H3 and ASF-1) 17 Figure 1D-3D ).
However, for peptides that bind to the c-site on top of the WD40 fold, the presence of salt as high as 25 mM significantly decreased the binding (Supplementary Figure 4D-6D ). These effects are consistent with the highly negatively charged c-site and the highly hydrophobic side pocket (Fig. 2) . We further evaluated the effect of detergents (Triton X-100, Tween 20 and NP-40) as well as reducing agents (DTT and TCEP) (Supplementary Figure 1E and 1F through 6E and 6F).
Optimum buffer conditions selected for performing each assay are shown in Table 2 . Total fluorescence was also measured at various concentrations of FITC-labeled peptides to be able to select the lowest peptide concentration that generates enough signal (Supplementary Figure 1G to 6G). This is particularly important for tight interactions. The presence of up to 5% DMSO in assay buffers did not have a dramatic effect on FP signal and was well tolerated with all of the peptides (Supplementary Figure 1H to 6H ).
Using the optimized assay conditions we assessed binding and determined the apparent K D values for the interaction of MTA1 (33 ± 13 nM), SUZ12 (6.4 ± 0.6 µM), PHF6 (201 ± 102 nM), FOG1 (488 ± 245 nM) and histone H3 (1.4 ± 0.2 µM) peptides to RBBP4 (Fig. 3) . Binding of histone H4 peptide ) to RBBP7 was also tested with a K D value of 135 ± 12 nM (Fig. 3C) .
Typically, FP-based screening relies on displacement of peptide from the binding site on the target protein by small molecules that compete with peptide 88, 89 . To discriminate against the term IC 50 value, which indicates the concentration of the compound that causes 50% reduction in activity of the target enzyme, we have previously introduced the term "K disp " which refers to the same concept but for displacement-based binding assays [88] [89] [90] . To evaluate displacement of the peptides from RBBP4/7 binding sites, we used unlabeled version of each peptide to compete and reduce the signal (Fig. 4) . Clear displacement of FITC-labelled peptides was observed for MTA1 (K disp : 308 ± 15 nM), histone H4 (K disp : 662 ± 8 nM), PHF6 (K disp : 1.7 ± 0.2 µM), and FOG1 (K disp : 6.8 ± 3.3 µM) peptides (Fig. 4A, 4C, 4D and 4E ). All these peptides bind with K D values below 500 nM (Fig. 3) . For SUZ12 binding to RBBP4 with K D values of 6.4 µM, we detected no displacement by unlabeled peptide up to 10 µM (Fig. 4B) . This is probably because the range of concentrations used may not be high enough. However, we were unable to use higher concentrations of SUZ12 peptide due to low solubility. For histone H3 peptide, we only included a range of up to 1.5 µM (Fig. 4F ) to test the displacement as the signal at higher concentrations of peptide was dramatically fluctuating.
Although we could not show that the displacement of SUZ12 and histone H3 peptides is possible, we did not dismiss the assays for screening. Performing Z'-determination for assays with all six peptides (Fig. 5) indicated that the assay for RBBP7 with histone H4 has the highest Z'-factor (0.76; Fig. 5C ) followed by RBBP4 with SUZ12 (0.63; Fig. 5B ), histone H3 (0.59; Fig.   5F ) and MTA1 (0.55; Fig. 5A ). As expected, the assays for PHF6 and FOG-1 were not suitable for screening with Z'-Factors below 0.5 ( Fig. 5D and 5E ).
In conclusion, we provide assays for displacement of MTA1, SUZ12, histone H3 and H4
peptides that have been optimized for high throughput screening of RBBP4/7, enabling discovery of small molecule antagonists that could be used toward further investigating RBBP4/7 roles in cells and discovery of cancer therapeutics.
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